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1 These authors contribute equally to this work.Alternative splicing of tau exon 10 generates tau isoforms with three or four microtubule-binding
repeats, named 3R- or 4R-tau. Normal adult human brain expresses equal levels of them. Imbalance
of 3R-tau and 4R-tau associates with several tauopathies. Splicing factor 9G8 suppresses tau exon 10
inclusion and its function is regulated by phosphorylation. Here, we found that cyclic AMP-depen-
dent protein kinase (PKA) phosphorylated 9G8. The catalytic subunits a and b of PKA interacted with
9G8, and activation of PKA enhanced the interaction. Up-regulation of PKA activity prevented 9G8
from inhibition of tau exon 10 inclusion. These ﬁndings provide novel insights into the regulation
of tau exon 10 splicing and further our understanding of neurodegeneration associated with dysreg-
ulation of tau exon 10 splicing.
Structured summary of protein interactions:
9G8 physically interacts with PKA catalytic subunit by coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tau is a major neuronal microtubule-associated protein and
plays an important role in the assembly and stabilization of micro-
tubules. Hyperphosphorylation of tau leads to its aggregation into
neuroﬁbrillary tangles, a hallmark of Alzheimer disease (AD) and
related neurodegenerative diseases called tauopathies [1–4]. Adult
human brain expresses six tau isoforms from a single gene by
alternative splicing of exons 2, 3, and 10 of its pre-mRNA [5]. The
exon 10 encodes the second microtubule binding repeat [6], and
its alternative splicing generates tau isoforms with three or four
microtubule-binding repeats (3R-tau or 4R-tau), which are under
developmental and cell type-speciﬁc regulation. In normal adult
human brain, approximately equal levels of 3R- and 4R-tau are ex-
pressed [6,7]. Alteration in 3R-tau/4R-tau ratio is sufﬁcient to trig-
ger neurodegeneration in frontotemporal dementia and might also
play a role in other neurodegenerative disorders, such as Pick’schemical Societies. Published by E
chemistry, New York State
lities, 1050 Forest Hill Road,disease, corticobasal degeneration, or progressive nuclear palsy
[8–11].
Alternative splicing of tau exon 10 is regulated by several trans-
acting factors, including serine/arginine-rich (SR) proteins [12–16].
9G8, one of the SR proteins, is believed to be involved in both
constitutive splicing and alternative splicing of many pre-mRNAs.
It can help mRNA export to the cytoplasm and enhance the expres-
sion of unspliced mRNA [17]. Recent studies have shown that 9G8
inhibit tau exon 10 inclusion [18,19]. The localization and func-
tions of 9G8 are tightly regulated by phosphorylation, and overex-
pression of dual-speciﬁcity tyrosine-phosphorylated and regulated
kinase 1A (Dyrk1A) drives 9G8 to cytosolic compartment and
suppresses its function in tau splicing [19].
Cyclic AMP (cAMP)-dependent protein kinase (PKA) is a key ki-
nase that interacts with many proteins involved in the etiology of
AD as well as other tauopathies. It has been shown that PKA phos-
phorylates tau at several sites and primes phosphorylation of tau
by glycogen synthase kinase-3b [20]. In the absence of cAMP,
PKA is an inactive tetrameric holoenzyme consisting of two cata-
lytic (PKA-C) subunits and two regulatory (PKA-R) subunits. Stim-
ulation by cAMP dissociates PKA-R from PKA-C and causes a
fraction of the C subunit translocated into the nucleus. Apart from
regulation of transcription, little is known about the function of thelsevier B.V. All rights reserved.
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eral splicing factors and is involved in the pre-mRNA splicing,
including tau pre-mRNA [21–23]. The role of PKA in the 9G8 med-
iated alternative splicing of tau exon 10 was unclear. In the present
study, we found that PKA interacted with and phosphorylated 9G8.
Activation of PKA or overexpression of PKA-C inhibited 9G8-pro-
moted tau exon 10 exclusion. These results suggest that PKA may
be involved in the regulation of tau alternative splicing via 9G8
and in tau pathogenesis in AD and related tauopathies.
2. Materials and methods
2.1. Plasmids, antibodies, and other reagents
pCEP4/9G8 tagged with HA (hemagglutinin tag) at C-terminal
was a gift from Dr. Tarn of the Institute of Biomedical Sciences,
Academia Sinica, Taiwan. pCI/SI9-LI10 containing a tau minigene,
SI9/LI10, comprising tau exons 9, 10, and 11 and part of intron 9
and the full-length of intron 10, pCI/PKA-Ca, pCI/PKA-Cb and
pGEX-4T/9G8 have been described previously [19,24,25]. The cata-
lytic subunit of PKA, monoclonal anti-HA, forskolin and bd-cAMP
were bought from Sigma (Sigma, St. Louis, MO, USA). Polyclonal
anti-PKA-Ca and anti-PKA-Cb, siRNAs of mouse 9G8, human PKA-
Ca and PKA-Cb were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Polyclonal anti-CREB and anti-p-CREB were from Cell Sig-
naling Technology. Peroxidase-conjugated anti-mouse and anti-
rabbit IgG were obtained from Jackson Immuno Research Laborato-
ries (West Grove, PA, USA); Alexa 488-conjugated goat anti-mouse
IgG, and Alexa 555-conjugated goat anti-rabbit IgG and TO-PRO-3
iodide (642/661) were from Invitrogen (Invitrogen, Carlsbad, CA,
USA). The ECL kit was from Thermo Fisher Scientiﬁc (Rockford, IL,
USA), and [c-32P]ATP and [32P] orthophosphate were from MP Bio-
medicals (Irvine, CA, USA).
2.2. Cell culture and transfection
HEK-293FT, N2a and HeLa cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) at 37 C (5%
CO2). All transfections were performed in triplicates with Lipofect-
amine 2000 (Invitrogen, Carlsbad, CA, USA) or FuGENE HD (Roche
Diagnotics, Indianapolis, IN, USA) according to the manufacturer’s
instructions. For N2a cells, after transfection, the cells were differ-
entiated with 20 lM retinoic acid in DMEM supplemented with 2%
FBS.
2.3. In vitro phosphorylation of 9G8 by PKA
GST-9G8 or GST (0.2 mg/ml) was incubated with various con-
centrations of PKA-C in a reaction buffer consisting of 50 mM
HEPES, pH 6.8, 10 mM MgCl2, 10 mM b-mercaptoethanol, 1.0 mM
EGTA, and 0.2 mM [c-32P] ATP (500 cpm/pmol). After incubation
at 30 C for 30 min, the reaction was stopped by boiling with an
equal volume of 2 Laemmli sample buffer. The reaction products
were separated by SDS–PAGE. Incorporation of 32P was detected by
exposure of the dried gel to phosphor-image system (BAS-1500,
Fuji ﬁlm).
2.4. Mass spectrometry
GST-9G8 fusion protein was phosphorylated by PKA-C as de-
scribed above. In order to maximize the yield of the phosphory-
lated protein, the reaction was carried out for 1 h with high
amounts of the kinase (6:1 molar ratio of GST-9G8 and PKA-C).
The phosphorylated products were separated in SDS–PAGE andstained by Coomassie blue. The GST-9G8-containing gel piece
was in-gel trypsin digested. Proteolytic peptides were extracted
from the gel, followed by TiO2 immobilized metal afﬁnity chelate
(IMAC) enrichment for the phosphopeptides. The resulting fraction
was concentrated and reconstituted in 10 ll of 5% formic acid for
LC–MS/MS (liquid chromatography–mass spectrometry/mass
spectrometry) analysis.
2.5. Co-immunoprecipitation
HEK-293FT cells were transfected with pCEP4/9G8-HA for 40 h as
described above and treated with 5 or 10 lm forskolin for 8 h, then
the cells were washed twice with phosphate-buffered saline (PBS),
and lysed by sonication in lysate buffer (50 mM Tris–HCl, pH 7.4,
150 mM NaCl, 1 mM Na3VO4, 50 mMNaF, 2 mM EDTA, 1 mM PMSF,
and 10 lg/ml of aprotinin, leupeptin and pepstatin). The cell lysate
was centrifuged at 16000g for 10 min. The extract was incubated
with anti-HA overnight at 4 C, and then protein-G-conjugated
agarose beads were added. After 4 h of incubation at 4 C, the beads
were washed with lysate buffer twice and with tris-buffered saline
(TBS) twice, and bound proteins were eluted by boiling in 2
Laemmli sample buffer. The samples were subjected toWestern blot
analysis with the indicated primary antibodies.
2.6. Co-localization of PKA with 9G8
HeLa cells were plated in 24-well plates onto coverslips 1 day
before transfection at 30–40% conﬂuence. The cells were transfec-
ted with pCEP4/9G8-HA for 40 h and treated with 10 lm forskolin
for 30 min to activate PKA. Then the cells were ﬁxed with 4% para-
formaldehyde in PBS for 30 min at room temperature. After wash-
ing with PBS, the cells were blocked with 10% goat serum in 0.2%
Triton X-100/PBS for 2 h at 37 C, and then incubated with mouse
anti-HA (1:1000) and rabbit anti-PKA-C (1:50) overnight at 4 C.
The cells were incubated for 1 h with secondary antibody (Alexa
488-conjugated goat anti-mouse IgG, 1:1000, Alexa 555-conju-
gated goat anti-rabbit IgG, 1:1000) plus TO-PRO-3 iodide at room
temperature. After washing with PBS, the cells were mounted with
Fluoromount-G, and observed with a Nikon TCS-SP2 laser-scanning
confocal microscope.
2.7. Knockdown of 9G8 or PKA catalytic subunits with RNA
interference
N2a or HEK-293FT cells were transfected with various amounts
of short interfering RNAs, si9G8, siPKA-Ca and siPKA-Cb (Santa
Cruz Biotechnology) using Lipofectamine 2000 according to the
manufacturer’s instructions. After 48 h transfection, protein or
RNA was extracted as described above or below. The same amount
of scramble siRNA was used for control.
2.8. Quantitation of tau exon 10 splicing by reverse transcription–PCR
(RT–PCR)
Total cellular RNA was extracted from cultured cells by using
the RNeasy mini kit (Qiagen, GmbH, Germany) according to the
manufacturer’s instruction. One microgram of total RNA was used
for ﬁrst-strand cDNA synthesis with oligo-(dT)15–18 by using the
Omniscript reverse transcription kit (Qiagen). PCR was performed
by using PrimeSTAR™ HS DNA Polymerase (Takara Bio Inc., Otsu,
Shiga, Japan) with forward primer 50-GGTGTCCACTCCCAGTTCAA-
30 and reverse primer 50-CCCTGGTTTATGATGGATGTTGCCTAAT-
GAG-30 to measure alternative splicing of tau exon 10. The PCR
conditions were: 98 C for 5 min, 98 C for 10 s, 68 C for 40 s for
30 cycles and then 68 C 10 min for extension. The PCR products
Fig. 1. 9G8 inhibits tau exon 10 inclusion. (A) N2a cells were co-transfected with
pCI/SI9-LI10 mini-tau gene and pCEP4/9G8 or si9G8 using Lipofectamine 2000 for
48 h. The total RNA was then extracted and ampliﬁed by RT–PCR, followed by gel
electrophoresis to measure tau exon 10 splicing. (B) The ratio of inclusion/exclusion
of tau exon 10 was calculated after densitometry. The data are represented as
mean ± S.D. ⁄, p < 0.05; ⁄⁄, p < 0.01 vs. controls.
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mide staining and quantitated using the Molecular Imager system
(Bio-Rad).
2.9. Statistical analysis
Where appropriate, the data are presented as the means ± S.D.
Data points were compared by the unpaired two-tailed Student’s
t test, and the calculated p values are indicated in the ﬁgures.Fig. 2. PKA phosphorylates 9G8 in vitro. (A) GST-9G8 (0.2 mg/ml) was incubated with v
separated by SDS–PAGE and visualized with Coomassie blue staining (lower panel). The 3
device (BAS-1500, Fuji) (upper panel). (B) Incorporation of 32P into GST-9G8 was pl
spectrometry analysis of GST-9G8 phosphorylated by PKA. The red-colored sequence ind
indicates the 9G8 sequence. (D) Two phosphopeptides from the PKA-phosphorylated 9G3. Results
3.1. 9G8 inhibits tau exon 10 inclusion
To examine the role of 9G8 in tau exon 10 splicing, we co-trans-
fected mini-tau gene pCI/SI9-LI10 (comprising tau exons 9, 10, and
11 and part of intron 9 and the full-length of intron 10) together
with pCEP4/9G8 or si9G8 into N2a cells, and measured the alterna-
tive splicing products of tau exon 10 by RT–PCR. We found that
over-expression of 9G8 inhibits tau exon 10 inclusion markedly,
while knock-down of 9G8 by siRNA increased tau exon 10 inclu-
sion signiﬁcantly (Fig. 1), conﬁrming that 9G8 suppresses tau exon
10 inclusion. These results are consistent with our previous obser-
vations using HEK-293T cells [19].
3.2. PKA phosphorylates 9G8 in vitro
The biological activity of 9G8 is tightly regulated by its phos-
phorylation [19]. To study whether PKA phosphorylates and regu-
lates 9G8, we incubated GST-9G8 or GST with various
concentration of PKA catalytic subunit in vitro and found that
GST-9G8 was phosphorylated by PKA in an enzyme concentra-
tion-dependent manner (Fig. 2A and B). Under the same condition,
incubation of GST with PKA-C did not lead to any detectable phos-
phorylation [24].
To map the phosphorylation sites of 9G8 by PKA, we phosphor-
ylated GST-9G8 with 25 lg/ml of PKA for 60 min. The reactionarious concentrations of PKA-C at 30 C for 30 min, and the reaction products were
2P incorporated into 9G8 in the dried gel was measured by using a phosphorimaging
otted against PKA concentration. (C) The amino acid sequence derived by mass
icates the peptide fragments detected by LC–MS/MS, and the underlined sequence
8 samples detected by LC–MS/MS.
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trypsin digestion and LC–MS/MS. We identiﬁed two phosphopep-
tides from the phosphorylated GST-9G8 digest, which were both
located at the C-terminal end of 9G8 molecule (Fig. 2C and D). Be-
cause the known PKA-phosphorylated sites are not followed by
proline [26], we speculate that PKA phosphorylates 9G8 at serine
221 and serine 225.
3.3. PKA modulates tau exon 10 splicing and interacts with 9G8
To study whether activation of PKA affects 9G8-regulated tau
exon 10 splicing, we co-transfected pCI/SI9-LI10 with pCEP4/9G8
into HEK-293FT cells for 40 h, and then treated the cells with
10 lM forskolin or 50 lM bd-cAMP for 8 h to activate PKA. The
splicing products of tau exon 10 were then quantitated by RT–
PCR. We found that in the pCI/SI9-LI10-transfected HEK-293FT
cells, 9G8 overexpression inhibited and forskolin and bd-cAMP
promoted tau exon 10 inclusion (Fig. 3A). However, forskolin or
bd-cAMP treatment did not promote tau exon 10 inclusion inFig. 3. PKA modulates tau exon 10 splicing and interacts with 9G8. (A) The pCI/SI9-LI10-t
with either 10 lM forskolin or 50 lM bd-cAMP for 8 h, or both. The total RNA was then ex
splicing. The lower graph represents the mean ± S.D after densitometry. ⁄, p < 0.05; ⁄⁄, p
were then treated with 10 lM of forskolin for 8 h. The cells were ﬁxed and immune-s
conjugated goat anti-rabbit IgG (red) and Alexa 488-conjugated goat anti-mouse IgG (gre
were transfected with pCEP4/9G8-HA for 40 h and then treated with two concentratio
precipitate 9G8, and the immune-complex was detected by using antibodies against PK9G8-overexpressed cells (Fig. 3A), suggesting that 9G8 counteracts
tau exon 10 inclusion induced by activation of PKA.
9G8 mainly locates in the nucleus. Activation of PKA by cAMP
might lead to a fraction of the catalytic subunit translocating into
the nucleus. To study the subcellular localization of 9G8 and
PKA-C, we transfected pCEP4/9G8-HA into HeLa cells and then
examined their localizations by confocal microscopy after immu-
noﬂuorescent staining with anti-HA and anti-PKA-C. We found
that 9G8 was localized extensively in the nucleus and forskolin
treatment did change its subcellular localization (Fig. 3B). PKA cat-
alytic subunit (PKA-C) was located in both cytoplasm and nucleus.
A fraction of PKA-C in nucleus was co-localized with 9G8 (Fig. 3B).
Forskolin treatment increased PKA-C nuclear localization and en-
hanced its co-localization with 9G8 (Fig. 3B).
There are three isoforms, a, b, and c, of PKA catalytic subunits.
PKA-Ca and PKA-Cb express ubiquitously, but PKA-Cc only ex-
presses in testis [27–29]. To investigate the interaction of 9G8 with
PKA-Ca and b, we overexpressed HA-tagged 9G8 in HEK-293FT
cells for 48 h, immunoprecipitated 9G8 with anti-HA from the cellransfected HEK-293FT cells were transfected with pCEP4/9G8-HA for 40 h or treated
tracted and subjected to RT–PCR and gel electrophoresis to measure the tau exon 10
< 0.01. (B) HeLa cells were transfected with pCEP4/9G8-HA for 40 h, and some cells
tained by monoclonal anti-HA and polyclonal anti-PKA-C, followed by Alexa 555-
en), respectively. TO-PRO-3 (blue) was used for nuclear staining. (C) HEK-293FT cells
ns of forskolin for 8 h. The cell extracts were incubated with anti-HA to immune-
A-Ca and Cb. The arrows indicate PKA-C. HC, IgG heavy chain; LC, IgG light chain.
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noprecipitated by anti-HA with Western blots. We found that PKA-
Ca, but not PKA-Cb, was co-immunoprecipitated by anti-HA
(Fig. 3C), suggesting that 9G8 interacts with PKA-Ca, but not
PKA-Cb, at the basal condition.
To know whether activation of PKA enhances the interaction of
9G8 with PKA-C, we treated 9G8-overexpressed cells with 5 or
10 lM forskolin for 8 h to activate PKA and measured the levels
of PKA-Ca and PKA-Cb in anti-HA-9G8-immunoprecipitated com-
plexes. We found that both PKA-Ca and PKA-Cb were co-immuno-
precipitated by anti-HA from the cells treated with forskolin
(Fig. 3C), suggesting that activation of PKA enhances the interac-
tion of 9G8 with PKA-Ca and PKA-Cb.
3.4. Overexpression of PKA catalytic subunits modulates 9G8-regulated
tau exon 10 splicing
To study the effects of PKA and 9G8 on tau exon 10 splicing, we
overexpressed PKA-Ca, PKA-Cb and 9G8 individually and in combi-
nation in HEK-293FT cells transfected with pCI/SI9-LI10, and then
measured the splicing products of tau exon 10 by RT–PCR. We
found that overexpression of either PKA-Ca or PKA-Cb increased
the PKA kinase activity, as evidenced by marked increase in phos-
phorylation of its endogenous substrate CREB at Ser133 (pS133-
CREB) (Fig. 4A) and promoted tau exon 10 inclusion dramatically
(Fig. 4B) [24]. Co-overexpression of PKA-Ca or PKA-Cbwith 9G8 re-
versed 9G8’s inhibitory action on tau exon 10 inclusion (Fig. 4B).
These results indicate a negative regulation of PKA on 9G8’s func-
tion in tau exon 10 splicing.
4. Discussion
Alternative splicing of tau exon 10 results from action of trans-
acting factors, also named splicing factors, on cis-elements locatedFig. 4. PKA and 9G8 regulate tau exon 10 splicing. (A) HEK-293FT cells were transfected
and CREB were analyzed by Western blots and quantiﬁcation is shown in the lower pan
either PKA-Ca or PKA-Cb individually or in combination. The total RNA was extracte
Quantiﬁcation of the gel electrophoresis of the PCR products is shown in the lower panmainly on exon 10 and intron 10. 9G8 is a splicing factor, and its
overexpression suppresses tau exon 10 inclusion [12,19]. Down-
regulation of 9G8 by its siRNA signiﬁcantly promotes tau exon 10
inclusion, further supporting the involvement of 9G8 in the alter-
native splicing of tau exon 10. Like other SR proteins, the function
of 9G8 is tightly regulated by its phosphorylation [19]. In the pres-
ent study, we demonstrated for ﬁrst time that 9G8 is phosphory-
lated by PKA, which modulates 9G8-mediated tau exon 10 splicing.
PKA phosphorylates numerous proteins at Thr or Ser commonly
in the consensus sequence of R/KR/KX(X)T/S [26]. 9G8 contains 8 of
this motifs, 123RRRRS128, 125RRSRS130, 140RRYS144, 152RRSRS157,161
RRSRS165, 168RRSRS173, 176RRSRS181, 228KRSRS233, and 237RRSAS242,
suggesting that 9G8 is putative good substrate of PKA. These puta-
tive PKA phosphorylation sites are located at its RRM2 (RNA recog-
nition motif 2) and RS domain. In the present study, we
demonstrated that PKA phosphorylated 9G8 effectively in vitro.
We further identiﬁed two phospho peptides, 215SPSPKRSR222 and
223SPSGSPRR230, by mass-spectrum analysis. Because the known
PKA-phosphorylated sites are not followed by proline [26] and
two of the three Ser residues in each of the two identiﬁed peptides
are followed by proline, we speculate that PKA phosphorylates 9G8
at Ser221 and Ser225. However, these two sites do not belong to
any of the above-mentioned putative PKA-phosphorylated sites.
It is likely that there are other PKA phosphorylation sites of 9G8
that we failed to identify due to poor recovery of the trypsin-di-
gested peptides. These phosphorylation sites that we failed to
identify are probably located in the above consensus sequence.
These consensus motifs are rich of arginine/lysine residues. It is
not surprising that trypsin may had cleaved these sequences and
made the identiﬁcation of phospho-Ser and phospho-Thr within
these sequences difﬁcult.
PKA is activated by cAMP-induced dissociation of its regulatory
subunits from its catalytic subunits. A fraction of the catalytic sub-
unit can translocate into the nucleus and phosphorylates nucleic
proteins, such as 9G8. We also observed that activation of PKAwith pCI/PKA-Ca, or pCI/PKA-Cb. After 48 h transfection, the phosphorylated CREB
el. (B) pCI/SI9-LI10-transfected HEK-293FT cells were transfected with 9G8 or with
d 48 h later and the splicing products of tau exon 10 were detected by RT–PCR.
el. The data are represented as mean ± S.D. ⁄, p < 0.05; ⁄⁄, p < 0.01.
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the nucleus from the cytoplasm and enhanced its interaction with
9G8. 9G8 is also a shuttle protein and participates in the transpor-
tation of mRNA to cytoplasm [30]. The shuttle of 9G8 is regulated
by phosphorylation. Overexpression of both Dyrk1A and 9G8 led to
their translocation from the nucleus to the cytoplasm and thus
diminished their effects on tau exon 10 splicing [19]. In the present
study, we found that PKA had no effect on the subcellular localiza-
tion of 9G8 or its subnuclear localization.
Tau exon 10 alternative splicing is regulated by several splicing
factors, including 9G8, alternative splicing factor (ASF), and SC35.
ASF promotes tau exon 10 inclusion and its activity in tau exon
10 splicing is enhanced by PKA [31]. In contrast with ASF, 9G8 sup-
presses tau exon 10 inclusion [19] and PKA inhibits 9G8 sup-
pressed tau exon 10 inclusion. Thus, activation of PKA would
increase tau exon 10 inclusion through at least two splicing factors,
9G8 and ASF. We previously found that PKA is down-regulated in
AD brain [27]. Taken together, the down-regulated PKA may lead
to an imbalance of tau exon 10 splicing and increased 3R-tau via
9G8 and ASF in AD brain. Such an altered 4R-tau/3R-tau ratio has
been reported in AD [3,24,32].
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